美微达医疗是一家专注肿瘤介入治疗器械研发与产业化的高科技医疗公司。公司致力于通过自主创新，解决传统穿刺、活检和肿瘤消融技术中存在的临床安全性、 效率、并发症风险以及操作复杂等痛点。 目前，美微达医疗已在肿瘤介入治疗、术中导航与消融治疗等方向积累多条产品线，形成覆盖从诊断（活检）到治疗（消融）的完整介入器械体系。 # 核心产品与技 术介 绍 同轴穿刺热凝针：活检+止血"一体化" 近日， 专注肿瘤介入治疗领域的 美微达医疗 宣布完成 数千万元A+轮融资 。 本轮融资由翰驰基金领投，乐礼资本与匀升投资跟投。融资资金将主要用于新品开 发、创新医疗器械临床试验及临床推广，助力公司加速国产肿瘤介入治疗技术落地。 # 行业背景 随着肿瘤治疗向微创化、精准化方向发展，肿瘤介入治疗因其创伤小、恢复快、对患者身体负担低的特点，越来越受到临床重视。热消融、射频消融、微波消融等 局部消融技术，正成为肝癌、肺癌、肾癌等实体肿瘤的重要补充或替代方案。 微波消融（Microwave Ablation，MWA） 是一种成熟的热消融方式，通过微波能量使肿瘤组织内水分子震荡产生热量，从而使肿瘤发生凝固性坏死，适用于不能 耐受手术的患者。与传统射 ...

Core Viewpoint - The Hengqin Guangdong-Macao Deep Cooperation Zone has made significant progress in promoting Macao's economic diversification and integration with Hengqin over the past four years, focusing on institutional innovation, industrial collaboration, and the integration of livelihoods [2][8]. Policy Support - The establishment of the cooperation zone has led to the relocation of companies like Zhenjiankang Medical Technology to Hengqin, benefiting from favorable policies and support [3]. - As of July 2023, there are nearly 60,000 operating entities in the cooperation zone, with Macao-funded enterprises increasing by 57.49% since its inception [3]. Innovation Empowerment - The establishment of the Zhuhai Macao University Science Research Institute has facilitated cross-border research and development, enhancing the integration of Macao's research capabilities with Hengqin's industrial advantages [5][6]. - New regulations have been introduced to facilitate cross-border practice for Macao medical and legal professionals, with 1,669 professionals already practicing in the cooperation zone as of July 2023 [6]. Livelihood Integration - The "Macao New Neighborhood" project has been developed to provide comprehensive living services for Macao residents, with increasing numbers choosing to reside there [7]. - As of June 2023, the number of Macao residents living in the cooperation zone reached 23,749, a year-on-year increase of 30.1%, while those employed in the zone reached 5,762, up 14.1% [8].

Group 1: Company Developments - Hengqin Bihua Medical Laboratory successfully passed the ISO15189 accreditation site review, indicating that its quality management system and testing capabilities meet international standards [5] - Zhenjiankang Company received NMPA Class III medical device registration for two innovative products, bringing its total to seven Class III and four Class II medical device registrations [6] - Guangdong Taiwen Biological Engineering Co., Ltd. obtained a Class II medical device production license, marking compliance with national regulatory requirements in the field of in vitro diagnostic reagents [7] Group 2: Industry Initiatives - The dual-currency payment pilot program has expanded to six key commercial areas in Hengqin, facilitating small payments in both RMB and MOP, enhancing consumer experience [8] - The revised management measures for the Hengqin Guangdong-Macao Deep Cooperation Zone government investment fund were published, effective from August 13, 2025, focusing on key industry projects [9] - The newly issued support measures for financing development of small and micro enterprises in Hengqin include interest subsidies and risk compensation, with a maximum single financing risk compensation of 7.2 million yuan [10][11]